Pfizer says third dose of COVID-19 vaccine very effective against Delta variant
Published July 28, 2021 at 9:42 pm
A third-dose booster of the Pfizer/BioNTech COVID-19 vaccine — which has been a popular option for second doses in Mississauga and Brampoton — will strongly boost protection against the Delta variant, Pfizer suggests.
Data posted online by the pharmaceutical giant, which was intended for a company earnings call on Wednesday (July 28), shows that there were significant increases in antibody levels among subjects in clinical trials who had a third dose.
People who were aged 18 to 55 who received a third dose had antibody levels more than five times higher than they were following a second dose. Among older adults, the jump in antibody levels was more than 11 times higher. The data still needs to be peer-reviewed, but it could increase protection 100-fold.
Researchers’ notes suggests that there is emerging real-world data that “immunity against infection and symptomatic disease may wane.” They also suggest that they was a great increase in antibody production to protect against the Beta and Wild variants of COVID-19.
Pfizer also states clinical studies for a Delta variant vaccine are projected to begin in August.
Residents of both Mississauga and Brampton have been allowed to chose to receive the Pfizer-BioNTech vaccine for their second dose, even fellow mRNA vaccine Moderna is available. Hamilton’s public health unit has also made a similar policy change.
(Secondary photo via Pfizer.)Insauga's Editorial Standards and Policies